It was shown that the VEGF-VEGFR2 axis involved in the accumulation of immature Tregs, tyrosine kinase inhibitors might inhibit TCR signaling for Tregs survival and function, and the use of PI3K inhibitors in the mouse model may induce immunosuppression via Tregs, which suggests the possibility of combining Tregs anti-tumor therapy with targeted therapy [120]. Here, VEGFA is linked to neoplasm.